Tong Ren Tang Technologies Co Ltd

Tong Ren Tang Technologies Co Ltd maintains a strong liquidity position, with a current ratio of 5.72, indicating a robust ability to meet short-term obligations. The company's cash and equivalents amount to CNY 4.7 billion, significantly exceeding its short-term liabilities. The debt-to-equity ratio of 0.27 suggests a conservative capital structure, with long-term debt at CNY 2.0 billion and total equity at CNY 7.34 billion. Profitability metrics show a return on equity (ROE) of 5.4% and a return on assets (ROA) of 2.89%. These figures are below the industry median for ROE and ROA in the Pharmaceuticals sector, indicating that the company is generating returns at a moderate pace relative to its peers. Gross profit of CNY 2.47 billion and operating income of CNY 802 million reflect a healthy margin structure, but net income of CNY 396 million suggests some pressure from operating expenses. The company's revenue is concentrated in a single business segment, with no disclosed geographic breakdown. This lack of diversification may expose the company to sector-specific risks, particularly in the TCM and pharmaceutical markets. The absence of segment or geographic data limits the ability to assess exposure to regional economic shifts or regulatory changes. Looking ahead, Tong Ren Tang is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The company's revenue of CNY 6.48 billion in the latest period reflects a consistent performance, but the absence of growth drivers or expansion plans in the data suggests a conservative outlook. Risk factors for the company are currently low, with no immediate liquidity or dilution concerns identified. The company has not issued any recent equity, and the number of shares outstanding remains unchanged at 1.28 billion for both basic and diluted shares. However, the conservative capital structure and low debt levels may limit the company's ability to pursue aggressive growth opportunities. Recent filings and transcripts do not indicate any material events or strategic shifts. Analysts have assigned a mean price target of CNY 5.50, with a median and high target also at CNY 5.50, suggesting a consensus view of stability rather than growth. The mean recommendation of 2.00 (on a scale of 1 to 5) indicates a "buy" rating, but the absence of strong-buy recommendations suggests limited upside potential.